TBC Janssen-Cilag Pty Ltd
Product name
TBC
Sponsor
Accepted date
May-2024
Active ingredients
daratumumab
Proposed indication
For the treatment of patients with newly diagnosed multiple myeloma.
Application type
C (new indication)
Publication date
May-2024